Figure 4

LPS-treated mice experience insignificant benefit when treated with BMSC-CM compared to BMSC-CM with neutralizing antibodies targeting sTNFR1 and sVEGFR1. 10 ug LPS were administered IP to each mouse to induce endotoxemia, followed by either 1 ml of saline (control), 1 ml BMSC-CM, 1 ml BMSC-CM with neutralizing sTNFR1 antibody, or 1 ml BMSC-CM with neutralizing sVEGFR1 antibody IP. BMSC-CM treated mice experienced a significantly greater survival benefit in comparison to control mice (P = 0.0454). Mice given BMSC-CM with neutralizing sTNFR1 antibody also experienced a significantly greater survival benefit compared to control (P = 0.0225). The BMSC-CM with neutralizing sVEGFR1 antibody group did not differ significantly from the control (P = 0.106) or from the neutralizing sTNFR1 antibody group (P = 0.528). Finally, neither group that received a neutralizing soluble receptor antibody had a significantly different survival benefit compared to the BMSC-CM treated group (neutralizing sTNFR1 antibody vs BMSC-CM P = 0.563; neutralizing sVEGFR1 antibody vs BMSC-CM P = 0.237).